NASDAQ$ATRA
Atara Biotherapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Atara reported financial results for the first quarter of 2021 and provided recent business highlights.
Atara Biotherapeutics reported a net loss of $78.3 million, or $0.86 per share, for the first quarter of 2021. The company's cash, cash equivalents, and short-term investments totaled $435.2 million as of March 31, 2021. License and collaboration revenue was $3.6 million for the quarter, stemming from the Bayer Collaboration Agreements.
- Atara is progressing toward alignment with the FDA on the content of CMC Module 3 for tab-cel®.
- BLA submission for tab-cel® is expected in Q3 2021, and MAA submission in EU is expected in Q4 2021.
- Enrollment is progressing in the ATA188 Phase 2 trial for progressive forms of MS, with an interim analysis planned for H1 2022.
- The global strategic collaboration with Bayer, including ATA2271 and ATA3271, is progressing well with successful launch of joint governance and activities.
Headline financials
Revenue & EPS history
Atara · Revenue · Quarterly
$3.55M
Forward guidance
Atara believes that its cash as of March 31, 2021 together with projected revenue from U.S. tab-cel® sales is sufficient to fund its operations into 2023.
Tailwinds
- Completing a BLA submission in Q3 2021 pending alignment with the FDA.
- Submitting an EU Marketing Authorization Application (MAA) for tab-cel® in patients with EBV+ PTLD expected in Q4 2021.
- Presenting data from the Phase 3 ALLELE study at an appropriate congress in Q4 2021.
- Presenting long-term two-year clinical data from the Phase 1 open-label extension (OLE) and translational data from the Phase 1 study in H2 2021.
- Submitting an IND for ATA3219 in Q4 2021 / Q1 2022.
Headwinds
- The costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success
- The ongoing COVID-19 pandemic, which may significantly impact Atara's business, research, clinical development plans and operations
- COVID-19 may impact Atara's ability to access capital
- COVID-19 may impact the value of Atara's common stock
- The sufficiency of Atara’s cash resources and need for additional capital
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
-2.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.6%
Avg return
30 days after
37%
17 / 46 earnings
Positive
+36.3%
Q2 2022
Best reaction
-24.2%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +11.5% | +9.6% | — | |
| Q4 2025 | -0.6% | -16.4% | -10.7% | |
| Q3 2025 | -1.3% | +4.3% | +43.3% | |
| Q1 2025 | +4.8% | +6.8% | +6.3% | |
| Q4 2024 | +3.9% | -9.2% | +10.6% | |
| Q3 2024 | +21.2% | +2.0% | -7.0% | |
| Q2 2024 | +5.8% | -7.5% | +9.6% | |
| Q1 2024 | -6.3% | +6.9% | -6.5% | |
| Q4 2023 | +3.6% | +4.0% | -1.4% | |
| Q3 2023 | -7.8% | +2.3% | -49.8% | |
| Q2 2023 | -16.4% | -7.1% | -31.6% | |
| Q1 2023 | -16.2% | -26.5% | -43.3% | |
| Q4 2022 | -12.6% | -18.7% | -48.2% | |
| Q3 2022 | -18.0% | +8.5% | +0.2% | |
| Q2 2022 | +36.3% | +69.8% | +32.3% | |
| Q1 2022 | -5.3% | -22.2% | -29.7% | |
| Q4 2021 | -22.6% | -32.9% | -30.4% | |
| Q3 2021 | -3.1% | -4.4% | -8.9% | |
| Q2 2021 | +0.8% | -1.5% | +17.9% | |
| Q1 2021 | -3.9% | -3.3% | -5.1% | |
| Q4 2020 | +1.0% | -4.2% | -14.4% | |
| Q3 2020 | -5.9% | +9.0% | +72.0% | |
| Q2 2020 | +1.9% | +3.5% | +4.8% | |
| Q1 2020 | +4.9% | +17.5% | +11.7% | |
| Q4 2019 | +8.8% | +11.5% | -24.4% | |
| Q3 2019 | +10.2% | +6.9% | +15.0% | |
| Q2 2019 | +10.6% | +17.3% | +16.4% | |
| Q1 2019 | -24.2% | -27.1% | -35.6% | |
| Q4 2018 | -13.3% | -8.5% | -7.4% | |
| Q3 2018 | -1.9% | -3.5% | +5.7% | |
| Q2 2018 | -2.1% | +0.5% | +9.1% | |
| Q1 2018 | -5.8% | +1.7% | +0.6% | |
| Q4 2017 | -10.6% | -8.6% | -9.5% | |
| Q3 2017 | -6.3% | -4.9% | +3.1% | |
| Q2 2017 | -3.3% | -3.6% | -1.3% | |
| Q1 2017 | -5.1% | -7.0% | -10.2% | |
| Q4 2016 | +21.4% | +16.8% | -1.2% | |
| Q3 2016 | +17.2% | +45.6% | +32.6% | |
| Q2 2016 | -9.5% | -14.7% | -14.3% | |
| Q1 2016 | -5.5% | — | — | |
| Q4 2015 | -18.5% | — | — | |
| Q3 2015 | +4.7% | — | — | |
| Q2 2015 | -11.4% | — | — | |
| Q1 2015 | -1.7% | — | — | |
| Q4 2014 | -5.9% | — | — | |
| Q3 2014 | -15.5% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro